These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 19525447)
21. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of Kim SY; Crook D; Rosskopf J; Lee JH Head Neck; 2024 Sep; 46(9):2284-2291. PubMed ID: 38712471 [TBL] [Abstract][Full Text] [Related]
23. Comparison of diffusion-weighted MR imaging and Schroeder C; Lee JH; Tetzner U; Seidel S; Kim SY Eur J Radiol; 2020 Sep; 130():109157. PubMed ID: 32652403 [TBL] [Abstract][Full Text] [Related]
24. Effect of time-of-flight technique on the diagnostic performance of 18F-FDG PET/CT for assessment of lymph node metastases in head and neck squamous cell carcinoma. Li CY; Klohr S; Sadick H; Weiss C; Hoermann K; Schoenberg SO; Sadick M J Nucl Med Technol; 2014 Sep; 42(3):181-7. PubMed ID: 24970897 [TBL] [Abstract][Full Text] [Related]
25. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. Scarfone C; Lavely WC; Cmelak AJ; Delbeke D; Martin WH; Billheimer D; Hallahan DE J Nucl Med; 2004 Apr; 45(4):543-52. PubMed ID: 15073248 [TBL] [Abstract][Full Text] [Related]
29. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer. Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143 [TBL] [Abstract][Full Text] [Related]
30. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422 [TBL] [Abstract][Full Text] [Related]
31. Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup. Zwirner K; Thorwarth D; Winter RM; Welz S; Weiss J; Schwenzer NF; Schmidt H; la Fougère C; Nikolaou K; Zips D; Gatidis S Strahlenther Onkol; 2018 Aug; 194(8):719-726. PubMed ID: 29564483 [TBL] [Abstract][Full Text] [Related]
32. PET monitoring of therapy response in head and neck squamous cell carcinoma. Schöder H; Fury M; Lee N; Kraus D J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408 [TBL] [Abstract][Full Text] [Related]
33. Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy. Yoon DH; Cho Y; Kim SY; Nam SY; Choi SH; Roh JL; Lee SW; Song SY; Lee JH; Kim JS; Cho KJ; Kim SB Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):118-25. PubMed ID: 20675065 [TBL] [Abstract][Full Text] [Related]
34. Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma. Prestwich RJ; Subesinghe M; Gilbert A; Chowdhury FU; Sen M; Scarsbrook AF Clin Radiol; 2012 Oct; 67(10):966-75. PubMed ID: 22595082 [TBL] [Abstract][Full Text] [Related]
35. FDG-PET and diffusion-weighted MRI in head-and-neck cancer patients: implications for dose painting. Houweling AC; Wolf AL; Vogel WV; Hamming-Vrieze O; van Vliet-Vroegindeweij C; van de Kamer JB; van der Heide UA Radiother Oncol; 2013 Feb; 106(2):250-4. PubMed ID: 23395065 [TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of Berwouts D; Madani I; Duprez F; Olteanu AL; Vercauteren T; Boterberg T; Deron P; Bonte K; Huvenne W; De Neve W; Goethals I Head Neck; 2017 Nov; 39(11):2264-2275. PubMed ID: 28833829 [TBL] [Abstract][Full Text] [Related]
37. Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT. Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H J Radiat Res; 2015 May; 56(3):553-60. PubMed ID: 25829531 [TBL] [Abstract][Full Text] [Related]
38. Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer. Wong KH; Panek R; Dunlop A; Mcquaid D; Riddell A; Welsh LC; Murray I; Koh DM; Leach MO; Bhide SA; Nutting CM; Oyen WJ; Harrington KJ; Newbold KL Eur J Nucl Med Mol Imaging; 2018 May; 45(5):759-767. PubMed ID: 29164301 [TBL] [Abstract][Full Text] [Related]
39. The Correlations Between MRI Perfusion, Diffusion Parameters, and 18F-FDG PET Metabolic Parameters in Primary Head-and-Neck Cancer: A Cross-Sectional Analysis in Single Institute. Han M; Kim SY; Lee SJ; Choi JW Medicine (Baltimore); 2015 Nov; 94(47):e2141. PubMed ID: 26632740 [TBL] [Abstract][Full Text] [Related]
40. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Due AK; Vogelius IR; Aznar MC; Bentzen SM; Berthelsen AK; Korreman SS; Loft A; Kristensen CA; Specht L Radiother Oncol; 2014 Jun; 111(3):360-5. PubMed ID: 24993331 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]